期刊文献+

心血管风险评估与阿司匹林一级预防 被引量:3

原文传递
导出
摘要 阿司匹林对冠心病二级预防的价值已得到肯定。抗栓试验协作组(Antithrombotic Triallists’Collaboration,ATT)荟萃分析287项随机临床对照研究结果显示,抗血小板治疗使严重心血管事件减少25%,其中非致死性心肌梗死减少33%,心血管死亡减少17%。一项荟萃分析入选既往心肌梗死(MI)、稳定性心绞痛及卒中的患者,发现小剂量阿司匹林(75~325mg/d)降低心血管事件21%,包括非致命性MI、非致命性卒中和心血管死亡。
作者 高润霖
出处 《中华内科杂志》 CAS CSCD 北大核心 2013年第10期875-878,共4页 Chinese Journal of Internal Medicine
  • 相关文献

参考文献23

  • 1Antithrombotic Trialists' Collaboration. Collaborative meta-analysisof randomised trials of antiplatelet therapy for prevention of death,myocardial infarction, and stroke in high risk patients. BMJ,2002,324:71-86.
  • 2Berger JS, Brown DL, Becker RC. Low-dose aspirin in patientswith stable cardiovascular disease: a meta-analysis. Am J Med,2008,121 ;4349.
  • 3Pearson TA,Blair SN, Daniels SR,et al. AHA Guidelines forPrimary Prevention of Cardiovascular Disease and Stroke: 2002Update : Consensus Panel Guide to Comprehensive Risk Reductionfor Adult Patients Without Coronary or Other AtheroscleroticVascular Diseases. American Heart Association Science Advisoryand Coordinating Committee. Circulation, 2002,106:388-391.
  • 4Conroy RM, Pyorala K, Fitzgerald AP, et al. Estimation of ten-year risk of fatal cardiovascular disease in Europe : the SCOREproject. Eur Heart J, 2003,24:987-1003.
  • 5Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronaryheart disease using risk factor categories. Circulation, 1998 , 97 :1837-1847.
  • 6National Cholesterol Education Program ( NCEP) Expert Panel onDetection,Evaluation,and Treatment of High Blood Cholesterol inAdults ( Adult Treatment Panel III) . Third Report of the NationalCholesterol Education Program ( NCEP ) Expert Panel onDetection,Evaluation,and Treatment of High Blood Cholesterol inAdults ( Adult Treatment Panel III) final report. Circulation,2002,106:3143-3421.
  • 7Perk J, De Backer G, Gohlke H, et al. European Guidelines oncardiovascular disease prevention in clinical practice ( version2012). The Fifth Joint Task Force of the European Society ofCardiology and Other Societies on Cardiovascular DiseasePrevention in Clinical Practice ( constituted by representatives ofnine societies and by invited experts). Eur Heart J,2012 , 33 :1635-1701.
  • 8Ridker PM, Paynter NP, Rifai N, et al. C-reactive protein andparental history improve global cardiovascular risk prediction : theReynolds Risk Score for men. Circulation, 2008 ,118: 2243 -2251.
  • 9Ridker PM,Buring JE,Rifai N,et al. Development and validationof improved algorithms for the assessment of global cardiovascularrisk in women: the Reynolds Risk Score. JAMA, 2007,297:611-619.
  • 10Liu J, Hong Y, D'Agostino RB Sr, et al. Predictive value for theChinese population of the Framingham CHD risk assessment toolcompared with the Chinese Multi-Provincial Cohort Study. JAMA,2004,291 :2591-2599.

二级参考文献49

同被引文献41

  • 1李小鹰.阿司匹林在动脉硬化性心血管疾病中的临床应用:中国专家共识(2005)[J].中华心血管病杂志,2006,34(3):281-284. 被引量:194
  • 2Depta JP, Bhatt DL. Should patients stop taking aspirin for primary prevention[J]. Cleve Clin J Med, 2015, 82(2) :91-96.
  • 3Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension ( ESH ) and of the European Society of Cardiology (ESC)[J]. J Hypertens, 2013, 31 (7):1281-1357.
  • 4VanWormer JJ, Miller AW, Rezkalla SH. Aspirin overutilization for the primary prevention of cardiovascular disease [ J ]. Clin Epidemiol, 2014, 6:433-440.
  • 5Hira RS, Kennedy K, Nambi V, et al. Frequency and practice- level variation in inappropriate aspirin use for the primary prevention of cardiovascular disease: insights from the National Cardiovascular Disease Registry's Practice Innovation and Clinical Excellence registry[ J]. J Am Coil Cardiol, 2015, 65 (2) : 111- 121.
  • 6Liu J, Zhao D, Liu J, et al. Prevalence of diabetes mellitus in outpatients with essential hypertension in China: a cross-sectional study[J]. BMJ Open, 2013, 3( 11 ) :e003798.
  • 7Campbell CL, Smyth S, Montalescot G, et al. Aspirin dose tor tlae prevention of cardiovascular disease : a systematic review [J]. JAMA, 2007, 297 ( 18 ) :2018-2024.
  • 8Yusuf S, Islam S, Chow CK, et al. Use of secondary prevention drugs for cardiovascular disease in the community in hish-income, middle-income, and low-income countries ( the PURE Study ) : a prospective epidemiological survey [J]. Lancet, 2011, 378 (9798) : 1231-1243.
  • 9Annemans L, Wittrup-Jensen K, Bueno H. A review of international pharmacoeconomic modds assessing the use of aspirin in primary prevention[J]. J Med Econ, 2010, 13(3) :418-427.
  • 10李小鹰.阿司匹林在心血管疾病一级预防中的争议与前景[J].中华心血管病杂志,2009,37(11):967-969. 被引量:3

二级引证文献64

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部